Shares of Moderna dropped 4.13% to $162.84 at 11:06 EST on Wednesday, after two sequential sessions in a row of gains. The Nasdaq Stock Market is sliding 0.06% to $12,575.30, after four consecutive sessions in a row of gains, on what at the moment seems, a somewhat negative trend exchanging session today.

Moderna’s last close was $169.86, 9.62% under its 52-week high of $178.50.

Moderna’s Sales

Moderna’s sales growth is 1428.1% for the ongoing quarter and 13065.3% for the next. The company’s growth estimates for the current quarter is a negative 48.6% and positive 565.7% for the next.

Moderna’s Revenue

Year-on-year quarterly revenue growth grew by 826.4%, now sitting on 246.7M for the twelve trailing months.

Moderna’s Stock Top and Bottom Yearly Value

Moderna’s stock is valued at $162.84 at 11:06 EST, under its 52-week high of $178.50 and way above its 52-week low of $17.68.

Moderna’s Moving Average

Moderna’s worth is way above its 50-day moving average of $96.34 and way above its 200-day moving average of $75.22.

Previous days news about Moderna

Moderna shares rally as Canada doubles vaccine order. According to MarketWatch on Mon Dec 7, “Shares of Moderna Inc. rallied 1.3% in morning trading Monday, after the biotechnology company said the Canadian government has doubled its order commitment for has gained 7.8%.”

Moderna says swiss government has increased its covid vaccine order to 7.5 million doses from 4.5 million. According to MarketWatch on Tue Dec 8, “Moderna could ship its COVID-19 vaccine as soon as December if regulatory approval is granted this month,’ the company said in a statement.”


Please enter your comment!
Please enter your name here